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BACKGROUND: Macrophage inhibitory cytokine-1(MIC-1) is a potential modulator of systemic inflammation and nutritional depletion,
both of which are adverse prognostic factors in oesophago-gastric cancer (OGC).
METHODS: Plasma MIC-1, systemic inflammation (defined as plasma C-reactive protein (CRP) of X10mgl
–1 or modified Glasgow
prognostic score (mGPS) of X1), and nutritional status were assessed in newly diagnosed OGC patients (n¼293). Healthy
volunteers (n¼35) served as controls.
RESULTS: MIC-1 was elevated in patients (median¼1371pgml
–1; range 141–39053) when compared with controls
(median¼377pgml
–1; range 141–3786; Po0.001). Patients with gastric tumours (median¼1592pgml
–1; range 141–12643)
showed higher MIC-1 concentrations than patients with junctional (median¼1337pgml
–1; range 383–39053) and oesophageal
tumours (median¼1180pgml
–1; range 258–31184; P¼0.015). Patients showed a median weight loss of 6.4% (range 0.0–33.4%),
and 42% of patients had an mGPS of X1 or plasma CRP of X10mgl
–1 (median¼9mgl
–1; range 1–200). MIC-1 correlated
positively with disease stage (r
2¼0.217; Po0.001), age (r
2¼0.332; Po0.001), CRP (r
2¼0.314; Po0.001), and mGPS (r
2¼0.336;
Po0.001), and negatively with Karnofsky Performance Score (r
2¼ 0.269; Po0.001). However, although MIC-1 correlated weakly
with dietary intake (r
2¼0.157; P¼0.031), it did not correlate with weight loss, BMI, or anthropometry. Patients with MIC-1 levels in
the upper quartile showed reduced survival (median¼204 days; 95% CI 157–251) when compared with patients with MIC-1 levels
in the lower three quartiles (median¼316 days; 95% CI 259–373; P¼0.036), but MIC-1 was not an independent prognostic
indicator.
CONCLUSIONS: There is no independent link between plasma MIC-1 levels and depleted nutritional status or survival in OGC.
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Systemic inflammation has been linked with adverse survival in a
variety of cancer types (Falconer et al, 1995; Scott et al, 2002;
Hefler et al, 2008). This association could be explained by a variety
of tumour-related phenomena, including enhanced tumour
progression (Hefler et al, 2008), angiogenesis (Krzystek-Korpacka
et al, 2008), and metastasis (Weinstein et al, 1984). However, the
presence of systemic inflammation has also been linked with both
hypermetabolism (Falconer et al, 1994) and reduced food intake
(Fearon et al, 2006), two key components of the cachexia
syndrome that is known to result in shortened survival in
patients with advanced malignancy (Fearon et al, 2006). The
mechanisms by which systemic inflammation arises in cancer
patients are not established clearly. One hypothesis is that
interaction between host and tumour cells within the tumour
mass results in activation of peripheral blood mononuclear cells
(PBMCs) (O’Riordain et al, 1999). The latter circulate to distant
target organs in which enhanced cytokine/mediator production
results in the generation of a systemic inflammatory response.
Target organs include the liver (production of acute-phase
proteins, e.g., C-reactive protein (CRP); O’Riordain et al, 1999),
the brain (induction of anorexia; Buchanan and Johnson, 2007),
and skeletal muscle (induction of protein degradation and net
amino-acid mobilisation; Acharyya et al, 2005; Dejong et al, 2005).
We have shown previously increased pro-inflammatory cytokine
release by PBMCs in patients with elevated plasma CRP
concentrations (O’Riordain et al, 1999). The ability of such PBMCs
to induce acute-phase protein production from co-cultured human
hepatocytes seemed to be IL-6 dependent (O’Riordain et al, 1999).
In patients with oesophago-gastric cancer (OGC; in which systemic
inflammation is associated with weight loss and shortened
survival), we have previously shown that tumour IL-1b
overexpression and chronic inflammatory cell infiltrate are
independent factors influencing systemic inflammation (Deans
et al, 2006). However, the precise role of various pro-inflammatory
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scytokines within human tumours in the generation of a systemic
response is still incompletely understood.
Macrophage inhibitory cytokine-1 (MIC-1) is a divergent
member of the transforming growth factor-b superfamily that is
produced by macrophages in response to activation (Bootcov et al,
1997). MIC-1 is not expressed in most human tissues at basal
conditions (except the placenta) but is expressed at high
concentrations during inflammation and injury (Fairlie et al,
1999; Schober et al, 2001). MIC-1 is overexpressed by malignant
melanoma cells and is associated with tumourigenicity (Boyle et al,
2009). High serum concentrations of MIC-1 have been observed in
patients with pancreatic (Koopmann et al, 2004, 2006), gastric
(Baek et al, 2009), and breast cancer (Welsh et al, 2003), and have
been associated with adverse survival in colorectal cancer (Brown
et al, 2003) and glioblastoma (Shnaper et al, 2009). In prostate
cancer, high patient serum levels of MIC-1 have been associated
with increased disease stage (Selander et al, 2007), docetaxel
resistance (Zhao et al, 2009), and adverse survival (Brown et al,
2009). In prostate cancer bone metastases, MIC-1 induced
osteoclast activation (Wakchoure et al, 2009). In mice bearing
human prostate cancer xenografts, elevated MIC-1 concentrations
were associated with marked weight, fat, and lean tissue loss that
was mediated by decreased food intake and was reversed by an
antibody to MIC-1 (Johnen et al, 2007). In addition, normal mice
administered systemic MIC-1, and transgenic mice overexpressing
MIC-1, showed hypophagia and reduced body weight (Johnen
et al, 2007). In a small group of cachectic prostate cancer patients
(n¼26), serum MIC-1 concentrations were significantly associated
with weight loss and weakly correlated with serum IL-6 (Johnen
et al, 2007).
To determine whether MIC-1 is associated with inflammatory
and nutritional status, we aimed to measure circulating concen-
trations of MIC-1 in a large cohort (n4250) of patients with OGC,
a disease strongly associated with cachexia, and to analyse the
relationships between MIC-1, systemic inflammation, nutritional
status, and survival.
MATERIALS AND METHODS
Patients and controls
All patients provided written, informed consent, and the study was
approved by the Lothian Research Ethics Committee. Patients with
a new histological diagnosis of OGC were recruited (n¼293; 198
males and 95 females). Whole blood was taken at diagnosis for
plasma analysis of MIC-1 and CRP concentration. Staging was
carried out according to the AJCC/UICC system (Sobin and
Wittekind, 2002). The majority of patients (n¼186) were followed
up until death. A healthy control cohort (n¼35; 25 males, 10
females, median age 29years, range 24–85), composed of
laboratory and hospital staff (n¼28) and hospital patients
undergoing minor operative procedures for benign conditions
(n¼7), was recruited for comparative MIC-1 analysis. Exclusion
criteria for controls included recent weight change, ill-health, or
underlying inflammatory illness (e.g., rheumatoid arthritis).
Nutritional assessment
At recruitment, pre-illness stable weight was self-reported by
patients and percentage weight loss was calculated (Deans et al,
2009). Height was measured using a wall-mounted stadiometer
with the patient standing erect without shoes. Patients were
weighed on spring balance scales without shoes and wearing light
clothing. Mid-arm circumference (MAC) was measured at the mid-
point between the acromion and olecranon processes. Triceps
skinfold thickness (TSF) was measured with Harpenden skin
callipers (Holtain, Crymych, UK). Mid-arm muscle circumference
(MAMC) was calculated according to the formula: MAMC¼MAC-
[p TSF]. Karnofsky performance score (KPS) was documented
in all patients by the recruiting physician. As surrogates of
dietary intake, dysphagia score (normal swallowing¼0; dysphagia
to solids¼1; dysphagia to softened foods¼2; dysphagia to
liquids¼3; and total dysphagia¼4) and subjective diet score
(normal dietary intake¼1; reduced dietary intake¼2; and
poor dietary intake¼3) were assessed in a subset of patients
(n¼188). Cachexia was defined as weight loss of X10%
when compared with pre-morbid weight. Control subjects
did not undergo nutritional assessment beyond confirmation of
weight stability.
Total plasma MIC-1 concentration determination
Samples were examined in duplicate using a well-established
sandwich ELISA as previously described (Moore et al, 2000). In
brief, the mouse MAb 26G6H6 was used for antigen capture; and
the sheep PAb 233-P was used for detection (Moore et al, 2000;
Fairlie et al, 2001; Brown et al, 2002). The hMIC-1 plasma
concentration was determined by reference to a standard curve
constructed using recombinant hMIC-1 as the standard. All
samples had duplicate values with a coefficient of variation (CV)
of o10%. Assay performance was monitored additionally using
standard diagnostic laboratory procedures.
Assessment of systemic inflammation
Systemic inflammation was determined in two ways. In all patients,
the presence of a plasma CRP concentration of X10mgl
–1 was
used to define an acute-phase protein response (APPR). In a subset
of patients (n¼197), plasma albumin concentration was deter-
mined, and thus calculation of a systemic inflammation-based
score, the modified Glasgow Prognostic Score (mGPS) (McMillan,
2009), was performed. The mGPS was calculated as follows:
patients with an elevated level of CRP (410mgl
–1) were allocated
a mGPS of 1 or 2, depending on the absence or presence of
hypoalbuminaemia (o35gl
–1), whereas patients showing no
elevated level of CRP (p10mgl
–1) were allocated a mGPS of 0.
Plasma CRP and albumin concentrations were assayed using
automated methods on Olympus AU 2700 and Olympus 640
analysers, respectively (Olympus Diagnostica GmbH (Irish
Branch), Lismeehan, Ireland), in the Department of Clinical
Chemistry, Royal Infirmary of Edinburgh (fully accredited by
Clinical Pathology Accreditation (UK) Ltd). Appropriate IQC
were included, with CVs typically 3.4% at concentrations of o15mgl
–1
and 1.6% at 80mgl
–1for CRP, and o3.0% at all concentrations for
albumin.
Statistical analysis
All statistical analyses were performed using Statistical Package for
Social Services version 13.0 (SPSS 13.0; Chicago, IL, USA). Plasma
MIC-1 data are presented as box plots. Mild outliers (MIC-1
concentration more than 1.5 times the interquartile range (IQR)
above the third quartile) are represented as circles and extreme
outliers (MIC-1 concentration more than 3 times the IQR above
the third quartile) are presented as stars. For visual clarity, the
y axes are limited to a maximum MIC-1 concentration of 5000 or
8000 pgml
–1. Differences between the distribution functions of
data for three or more subject groups were determined using
Kruskal–Wallis test (shown in text and figure legends). Subse-
quent analysis for determining differences between any two groups
was determined using Mann–Whitney U test (shown in figures).
All quoted P-values are two tailed. Correlation analysis was
performed using non-parametric Spearman’s rank correlation
coefficient. Linear regression was used for analysing the relation-
ship between CRP and MIC-1. Significance levels for the
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sexplanatory variables of interest were 0.10 to enter stepwise into
the model. Survival analyses were performed on those patients
followed until death using Kaplan–Meier plots and Cox’s
proportional hazards models. For construction of the latter model,
treatment regimen was defined as either surgery with curative
intent, radical chemo/radiotherapy with curative intent, chemo/
radiotherapy with palliative intent, or nil. Statistical significance
was set at Po0.05 level.
RESULTS
Patient demographics
Oesophago-gastric cancer patients showed a median weight loss of
6.4% (range 0.0–33.4%; Table 1), and 34% of patients had lost
X10% body weight, consistent with significant cachexia. Further-
more, median BMI, MAMC, and TSF measures were lower than
those reported in healthy elderly populations (Corish and
Kennedy, 2003). In all, 42% of patients (n¼123) showed plasma
CRP concentrations of X10mgl
–1consistent with the presence of
an APPR. Of the assessed patients, 29.9% (59 out of 197) had a
mGPS of 1, and 13.7% (27 out of 197) had a mGPS of 2.
Plasma MIC-1 concentrations are elevated in
oesophago-gastric cancer
Plasma MIC-1 was elevated in OGC patients (median 1371pgml
–1;
range 141–39053) when compared with controls (median
377pgml
–1; range 141–3786; Po0.001; Figure 1). Patients with
gastric tumours (median 1592pgml
–1; range 141–12643) showed
higher MIC-1 concentrations than patients with oesophago-gastric
junction (OGJ; median 1337pgml
–1; range 383–39053) and
oesophageal tumours (median 1180pgml
–1; range 258–31184;
P¼0.015; Figure 2). Patients with poorly differentiated tumours
Table 1 Demographics, nutritional status, and plasma concentrations of
inflammatory mediators of the oesophago-gastric cancer patients. Data are
presented as medians with ranges.
Patients (n¼293)
Male:female 198:95
Age (years) 70 (26–91)
Tumour site
Oesophageal 139
OGJ 51
Gastric 103
Histology
Adenocarcinoma 242
Squamous 43
Undifferentiated 6
Neuroendocrine 2
Disease stage
I3 6
II 45
III 106
IV 97
Unknown 46
Body mass index (kgm
–2) 24.6 (13.9–46.7)
Weight loss (% loss of pre-morbid weight) 6.4 (0.0–33.4)
Mid-arm muscle circumference (cm) 23.8 (15.6–32.10)
Triceps skin-fold thickness (mm) 12.0 (3.0–52.0)
KPS 90 (30–100)
CRP (mgl
–1) 9.0 (1.0–200.0)
MIC-1 (pgml
–1) 1246.5 (140.7–39052.9)
Abbreviations: CRP¼C-reactive protein; KPS¼Karnofsky performance score;
MIC-1¼macrophage inhibitory cytokine-1.
P<0.001
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Figure 1 Box plot showing increased plasma MIC-1 concentration in
oesophago-gastric cancer patients when compared with the controls
(Po0.001).
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Figure 2 Box plot showing increasing plasma MIC-1 concentration with
increasing distal situation of the primary tumour (P¼0.015).
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Figure 3 Box plot showing increasing plasma MIC-1 concentration with
worsening tumour grade (P¼0.010).
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s(median 1480pgml
–1; range 245–9000) showed higher MIC-1
concentrations than patients with moderately differentiated
(median 1103pgml
–1; range 378–6646) and well-differentiated
tumours (median 875pgml
–1; range 710–1407; P¼0.010;
Figure 3). Plasma MIC-1 concentration also increased with
worsening disease stage (Figure 4) and increasing mGPS (Figure 5).
Relationship of MIC-1 with systemic inflammation and
nutritional status
Plasma MIC-1 concentration correlated positively with disease
stage (r
2¼0.217; Po0.001), patient age (r
2¼0.332; Po0.001), CRP
(r
2¼0.314; Po0.001), and mGPS (r
2¼0.336; Po0.001), and
correlated negatively with KPS (r
2¼ 0.269; Po0.001; Table 2).
Plasma MIC-1 also correlated weakly with diet score (r
2¼0.157;
P¼0.031) but did not correlate with dysphagia score or any of the
nutritional and anthropometric parameters measured. However,
there was a small but significant increase (18.9%) in plasma MIC-1
between patients who had lost X10% weight (median 1493pgml
–1;
range 258–31184) compared with those who had not (median
1256pgml
–1; range 141–39053; P¼0.036). In contrast, both CRP
(r
2¼0.247; Po0.001) and mGPS (r
2¼0.280; Po0.001) correlated
with weight loss, and mGPS also correlated negatively with MAMC
(r
2¼ 0.318; Po0.001; Table 2). Furthermore, there was a highly
significant increase in CRP and mGPS between patients who had
lost X10% weight compared with those who had not (median CRP
16.5 vs 6.0mgl
–1; median mGPS 1 vs 0; P¼0.001 for both tests).
The relationship between MIC-1 and CRP was not linear, as dot-
plots showed wide variance of CRP with increasing MIC-1 (Figure 6).
However, assuming linearity, regression analysis showed that MIC-1
accounted for 5.9% of the variation in plasma CRP (Po0.001). In a
regression model of CRP (incorporating MIC-1, disease stage, tumour
grade, percentage weight loss, diet score and KPS, i.e., those factors
found to correlate with CRP), plasma MIC-1 concentration
(P¼0.003), diet score (P¼0.001), and tumour grade (P¼0.033)
were significant determinants (r
2¼0.179; Table 3). In a regression
model of percentage weight loss (incorporating disease stage, mGPS,
P=0.002
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Figure 4 Box plot showing increasing plasma MIC-1 concentration with
worsening disease stage (P¼0.002).
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Figure 5 Box plot showing increasing plasma MIC-1 concentration with
increasing modified Glasgow Prognostic Score (Po0.001).
Table 2 Correlations between inflammatory mediators and nutritional status
Inflammatory mediator Positive correlates r
2 P-value Negative correlates r
2 P-value
MIC-1 CRP 0.314 o0.001 Albumin  0.316 o0.001
mGPS 0.336 o0.001 KPS  0.269 o0.001
Age 0.332 o0.001
Tumour grade 0.234 0.002
Stage 0.217 o0.001
Diet score 0.157 0.031
CRP MIC-1 0.314 o0.001 Albumin  0.489 o0.001
Tumour grade 0.341 o0.001 KPS  0.257 o0.001
Stage 0.220 o0.001
% Weight loss 0.247 o0.001
Diet score 0.265 o0.001
mGPS MIC-1 0.336 o0.001 MAMC  0.318 o0.001
Tumour grade 0.268 0.001 KPS  0.362 o0.001
Stage 0.234 0.001
% Weight loss 0.280 o0.001
Diet score 0.262 o0.001
Abbreviations: CRP¼C-reactive protein; KPS¼Karnofsky performance score; MAMC¼mid-arm muscle circumference; mGPS¼modified Glasgow Prognostic Score;
MIC-1¼macrophage inhibitory cytokine-1.
MIC-1 in oesophago-gastric cancer
RJE Skipworth et al
668
British Journal of Cancer (2010) 102(4), 665–672 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sdiet score, and dysphagia score), all four factors were significant
determinants (r
2¼0.259; Table 3). Plasma MIC-1 concentration did
not qualify to enter the model.
Relationship of MIC-1 with survival
Patients with plasma MIC-1 concentrations in the upper quartile
(42270pgml
–1) showed worsened survival (median 204 days;
95% CI 157–251) when compared with patients with MIC-1
concentrations in the lower three quartiles (median 316 days; 95%
CI 259–373; P¼0.036; log-rank test; Figure 7). In Cox’s
proportional hazards model (incorporating MIC-1, CRP, percen-
tage weight loss, disease stage, tumour grade, patient age,
dysphagia score, diet score, and treatment regimen), disease stage
(Po0.001), treatment regimen (P¼0.003), CRP (P¼0.034), and
percentage weight loss (P¼0.002), but not plasma MIC-1
concentration, were significant determinants of survival (Table 4).
Substitution of mGPS for CRP within the model revealed stage,
treatment regimen, and weight loss as the only significant
determinants.
Table 3 Results of the regression models of CRP (r
2¼0.179) and percentage weight loss (r
2¼0.259) demonstrating significant determinants
Unstandardised coefficients
Standardised coefficients
95% CI for B
Model Factor B Standard error b tP - value Lower boundary Upper boundary
CRP (Constant)  35.759 13.387  2.671 0.008  62.213  9.305
MIC-1 0.005 0.002 0.231 3.001 0.003 0.002 0.008
Diet score 12.613 3.670 0.258 3.437 0.001 5.361 19.864
Tumour grade 9.977 4.628 0.165 2.156 0.033 0.832 19.123
% Weight loss (Constant)  3.788 2.107  1.798 0.074  7.946 0.370
Diet score 2.871 1.066 0.221 2.693 0.008 0.767 4.975
mGPS 2.491 0.835 0.205 2.983 0.003 0.843 4.140
Stage 1.459 0.639 0.161 2.284 0.024 0.198 2.719
Dysphagia score 1.182 0.583 0.155 2.028 0.044 0.031 2.333
Abbreviations: CI¼confidence interval; CRP¼C-reactive protein; mGPS¼modified Glasgow Prognostic Score; MIC-1¼macrophage inhibitory cytokine-1.
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Figure 7 Kaplan–Meier plot of survival of oesophago-gastric cancer
patients according to plasma MIC-1 concentration. Patients with MIC-1
concentrations in the upper quartile showed worsened survival (median
204 days; 95% CI 157–251) when compared with patients with MIC-1
concentrations in the lower three quartiles (median 316 days; 95% CI
259–373; P¼0.036, log-rank test).
Table 4 Results of the Cox’s proportional hazards model demonstrating significant determinants of oesophago-gastric cancer patient survival
95% CI
B SE Wald d.f. P-value Hazard ratio Lower boundary Upper boundary
Stage 0.682 0.177 14.902 1 o0.001 1.979 1.399 2.798
Treatment regimen 13.934 3 0.003
CRP 0.006 0.003 4.498 1 0.034 1.006 1.000 1.012
% Weight loss 0.038 0.013 9.232 1 0.002 1.039 1.014 1.065
Abbreviations: CI¼confidence interval; CRP¼C-reactive protein.
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sDISCUSSION
This study shows that plasma MIC-1 concentrations are elevated in
OGC patients when compared with controls. Furthermore,
increasing plasma MIC-1 concentrations are associated with
indicators of poor patient prognosis, including tumour grade
and stage. Elevated circulating concentrations of MIC-1 have also
been associated with poor prognostic indicators in other cancer
types, including prostate cancer (Selander et al, 2007; Brown et al,
2009), colorectal cancer (Brown et al, 2003), and glioblastoma
(Shnaper et al, 2009).
In this study, plasma MIC-1 also correlated significantly with
mGPS and plasma CRP concentration, suggesting that MIC-1
might have a role in the aetiology of systemic inflammation in
OGC (although linear regression implies that this may be a minor
effect). However, MIC-1 concentrations do not correlate with any
measured nutritional or anthropometric parameters, including
patient weight loss. In a recent cohort of 220 patients with OGC, we
have shown by multiple regression analysis that plasma CRP, stage
of disease, and dietary intake are independent variables in
determining the degree of weight loss (Deans et al, 2009). These
results are confirmed by this study. Given such importance of
systemic inflammation, disease stage, and dietary intake in the
genesis of weight loss in OGC patients, it is somewhat surprising
that although MIC-1 concentrations correlated with all three of
these variables in this study, there was no correlation with weight
loss. However, MIC-1 levels were slightly elevated in patients with
X10% weight loss when compared with patients without,
suggesting that MIC-1 may have a role in the maintenance, rather
than the initiation, of weight loss.
Studies in mice with xenografted prostate tumours have suggested
that the mechanism underlying MIC-1-induced weight loss is
hypophagia caused by reduced neuropeptide Y expression
and increased pro-opiomelanocortin expression in the hypothalamic
arcuate nucleus (Johnen et al, 2007). In patients with OGC, a
number of primary and secondary causes of reduced dietary intake
are at work simultaneously, including dysphagia (McKernan et al,
2008), early satiety (Davis et al, 2006), chronic nausea (McKernan
et al, 2008), alterations in circulating neuroendocrine hormones
(e.g., ghrelin (Isomoto et al, 2005) and leptin (Huang et al, 2005; Zhao
et al, 2007)), hypogeusia/hyposmia (Plata-Salaman, 2000), and
cytokine-induced central anorexia (Plata-Salaman, 2001; Turrin
et al, 2004). Assuming that MIC-1 may be a modulator of appetite
in humans, the complex constellation of additional factors also
controlling food intake may explain why plasma MIC-1 concentra-
tions did not correlate with nutritional status in this study.
Future studies of MIC-1 that record accurately calorific intake in
OGC patients are required to elucidate the anorectic effect of different
factors.
Another proposed mechanism of MIC-1-induced weight loss is
through paracrine effects on adipocytes (Ding et al, 2009).
Recombinant MIC-1 stimulates adiponectin secretion by human
adipocytes, thus potentially negatively regulating body fat mass
(Ding et al, 2009). However, in this study, MIC-1 did not correlate
with one measure of body fat, namely TSF. Furthermore, previous
studies have proven that the relationship between MIC-1 and fat
mass is clearly not understood fully, as both obesity and type II
diabetes mellitus are associated with increased circulating levels of
MIC-1 (Dosta ´lova ´ et al, 2009). However, the latter observation
might be consistent with a role for MIC-1 in the aetiology of
systemic inflammation.
An alternative hypothesis for explaining the lack of association
between plasma MIC-1 and nutritional status in OGC is that
circulating MIC-1 concentrations are simply not elevated
sufficiently to overcome regulatory mechanisms and induce
cachexia. In patients with prostate cancer and cachexia, serum
MIC-1 concentrations were significantly higher (mean 12416±s.d.
10235pgml
–1) (Johnen et al, 2007) than those measured in
the present cohort of OGC patients. Furthermore, in mice
xenografted with prostate tumours overexpressing human MIC-1,
only animals with serum concentrations of 48500pgml
–1showed
clinically significant levels of weight loss (Johnen et al, 2007). Of
the OGC patients in this study, only 5 (1.7%) showed plasma
concentrations of MIC-1 48500pgml
–1. In these individuals,
plasma CRP was also elevated (median 58mgl
–1; range 16–92)
but there was no significant reduction in BMI (median 30.1kgm
–2;
range 21.7–32.0) or increase in weight loss (median 6.5%;
range 0.0–12.5) compared with the rest of the group. The reasons
for low circulating MIC-1 concentrations in OGC patients
may include low levels of activation of MIC-1 through
p53-dependent mechanisms (Li et al, 2000; Albertoni et al, 2002;
Yang et al, 2003), as many oesophago-gastric tumours show p53
deletion, mutation, and loss of heterozygosity (Huang et al, 1992;
Renault et al, 1993).
In this study, elevated plasma MIC-1 was associated with
worsened survival on univariate but not multivariate analysis.
Such findings may vary depending on the definition of normal
MIC-1 concentration used. Other studies that have analysed
relatively large cohorts of healthy controls have suggested that
the upper limit of normal plasma MIC-1 concentration lies
between 1070 and 1600pgml
–1 (Li et al, 2000; Brown et al, 2003;
Koopmann et al, 2004, 2006), which is lower than the definition
used in this study. However, the present data also suggest that
plasma MIC-1 concentration may increase with patient age, thus
implying that the normal range is not static. A lack of age-matched
healthy controls could be considered a disadvantage in both
previous studies and this study.
The variation in plasma MIC-1 concentrations observed between
different tumour types, grades, and stages implicates a tumour-
specific mechanism in the induction of MIC-1 expression. MIC-1 is
often secreted in an unprocessed propeptide form that regulates
the balance between extracellular matrix stores and circulating
mature MIC-1 (Bauskin et al, 2005). The absence of propeptide in
xenograft animal tumour models is associated with a 20-fold
increase in serum MIC-1 (Bauskin et al, 2005). In low-grade
localised prostate cancer, the level of proMIC-1 stromal stores was
the best predictor of future disease relapse when compared with
other clinicopathological variables (Bauskin et al, 2005). The
mechanisms surrounding the processing and extracellular storage
of MIC-1 may represent one explanation for the observed
differences in plasma MIC-1 between different tumour variables.
In conclusion, although plasma MIC-1 correlates with tumour
grade, disease stage, dietary intake, and systemic inflammation, it
does not seem to mediate weight loss or nutritional depletion
significantly in OGC.
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